<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02521675</url>
  </required_header>
  <id_info>
    <org_study_id>2015-A00709-40</org_study_id>
    <nct_id>NCT02521675</nct_id>
  </id_info>
  <brief_title>Validation of Algorithms for Basal Insulin Rate Reductions in Type 1 Diabetic Patients Practising Physical Activity in Real Life Conditions</brief_title>
  <acronym>Diabrasport2</acronym>
  <official_title>Multicentre Randomized Cross-over Study Assessing in Type 1 Diabetic Patients With Pump Insulin the Non-inferiority of Glycemic Control Obtained With the Algorithms Tested in DIABRASPORT Versus the Rest Period Without Physical Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre d’Etudes et de Recherche pour l’Intensification du Traitement du Diabète</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no specific recommendations on the adjustments of the insulin treatment in the event
      of physical activity (PA) in T1D patients treated on insulin pump therapy. Patients often
      prefer additional carbohydrates intake rather than the reduction of their insulin doses
      because of the lack of specific algorithms.

      The DIABRASPORT 2 study aims to demonstrate that using algorithms DIABRASPORT, during a week
      of physical activity (PA), the incidence of hypoglycaemia is not different from that obtained
      during a week of rest without physical activity.

      It is a multi-center European, controlled, randomized, cross-over, study, in 100 T1D patients
      practicing an occasional AP.

      25 centers involved in this study.

      After agreeing to participate in the study, patients will read the information leaflet, ask
      questions to the investigator physician and they will date and sign the consent form. The
      investigator physician will do the same.

      They will be then drawn randomly via the electronic CRF (eCRF) to determine the order in
      which they will realize the rest vs DIABRASPORT sessions.

      The study will take place in 5 weeks:

      During the weeks Baseline and Diabrasport, patients will have to make 3 physical activity of
      30 to 60 minutes separated by at least 24 hours:

        -  moderate activity 3 hours after lunch

        -  intense activity 3 hours after lunch

        -  activity moderate 90 min after lunch They will use their usual algorithms (Cho intake or
           adjustment of the dose of insulin) during the week Baseline and they will use the
           Diabrasport algorithm during the week Diabrasport.

      Patients will be equipped with a holter Glycemic iPro2, Medtronic, whose data are hidden.

      During the week of rest, patients should do no physical activity during the week. They will
      be equipped with the Glycemic holter.

      Patients will have to fill a food survey the days they practice PA. Between each period, the
      patient must respect a period of wash-out for one week at least, during which he will be
      asked to not practice physical activity.

      Validation of algorithms simple, easy to implement, adaptable by patients, could help to
      improve balance metabolic and practice of sport among the T1D.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">January 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the number of hypoglycemic events, defined by any threshold crossing 60 mg / dL (3.33mmol / L), measured in the interstitial glucose sensor continuously over a period of 24h</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of time spent over 24 hours in the euglycemic range [70; 180] mg / dL ([3.89, 10] mmol / L)</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>percentage of time spent over 24 hours in hyperglycemia (&gt; 180 mg / dL) (&gt; 10 mmol / L)</measure>
    <time_frame>24h</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic events, defined by any threshold crossing 70 mg / dL (3.9 mml / L), and &lt;54 mg / dL (3 mmol / l) measured by interstitial continuous glucose sensors</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hyperglycemic events, defined by any crossing of the threshold of 180 mg / dL (10 mml / L), measured by continuous interstitial glucose sensors.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic goals analysis:</measure>
    <time_frame>1 week</time_frame>
    <description>percentage of time spent in the intervals [70; 180] and [80; 140] mg / dL, [3.89; 10] and [4.44; 7.78] mmol / L
percentage of time passes hypoglycemia (&lt;60mg / dL) (&lt;3.33 mmol / L)
percentage of time spent in hypoglycemia (&lt;54mg / dL) (&lt;3 mmol / L)
percentage of time spent in hypoglycemia (&lt;70mg / dL) (&lt;3.89 mmol / L)
percentage of time spent &lt;80 mg / dL; (&lt;4.44 mmol / L)
percentage of time spent in hyperglycemia (&gt; 180 mg / dL) (&gt; 10 mmol / L)
percentage of time spent&gt; 140 mg / dL (&gt; 7.78 mmol / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nadirs analysis of blood glucose during the night (value reached)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nadirs analysis of blood glucose during the night (time to onset)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of quantities of glucose administration consumed during and at the waning of physical activity</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of average values of continuous glucose measurements according to the period (DIABRASPORT, rest and Baseline) and at different times of the day and night.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis by subgroups, depending on the type of physical activity and its duration, a link between a typology of physical activity or patients, and the number of hypoglycemia events during or waning of physical activity</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of evaluation questionnaires intensity PA (Borg) and quality of life (EVA)</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between number of hypoglycemic events predicted by the prediction function &quot;DIABRASPORT&quot; and number of hypoglycemic events actually occurred.</measure>
    <time_frame>1 week</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Diabetes Mellitus, Type I</condition>
  <condition>Adjustment of Basal Insulin Flow Rate During Physical Activity</condition>
  <condition>Adjustment of Prandial Insulin in Case of Physical Activity</condition>
  <arm_group>
    <arm_group_label>Diabrasport then Rest</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rest then Diabrasport</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Between each period, the patient should respect a wash-out period of at least one week, during which they will be asked not to practice physical activity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Usual algorithm</intervention_name>
    <description>The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible</description>
    <arm_group_label>Diabrasport then Rest</arm_group_label>
    <arm_group_label>Rest then Diabrasport</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Diabrasport algorithm</intervention_name>
    <description>The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week &quot;test algorithms usual&quot; and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90min after lunch These activities shall not exceed one hour</description>
    <arm_group_label>Diabrasport then Rest</arm_group_label>
    <arm_group_label>Rest then Diabrasport</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Rest</intervention_name>
    <description>The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.
The patient goes home and he will not perform any physical activity during the week</description>
    <arm_group_label>Diabrasport then Rest</arm_group_label>
    <arm_group_label>Rest then Diabrasport</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Holter Glycemic Ipro2, Medtronic</intervention_name>
    <arm_group_label>Diabrasport then Rest</arm_group_label>
    <arm_group_label>Rest then Diabrasport</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient aged over 18 years

          -  Patient with type 1 diabetes for at least 1 year

          -  Patient receiving insulin pump under basal-prandial regimen for at least 3 months

          -  Patient practicing functional insulin therapy, or using a fixed plane defined food

          -  Patients with a stable basal rate for at least 1 week

          -  Patient practicing regular physical activity and reproducible identically

          -  Patient with HbA1c older than 3 months between 6.5% and 9.5% (HbA1c ≤ 6.5% ≤ 9.5%)

          -  Patients with BMI ≤ 35

          -  Patient who agreed to participate in the study and who signed an informed consent

          -  Patient not participating in another protocol

          -  Patient covered by social security

        Exclusion Criteria:

          -  Patients with a history of severe hypoglycemia without accidental cause in the 6
             months preceding the entry in the protocol

          -  Patient not receiving its hypoglycaemia below the threshold of 0.5 g / L

          -  Patient with perforating foot ulcer or a known history of heart disease or
             obliterative arteriopathy of the lower limbs, or a history of cerebrovascular
             accident, or ongoing proliferative retinopathy or renal failure

          -  Patient with poorly controlled hypertension

          -  Pregnant woman

          -  Patients deprived of liberty by judicial or administrative decision, patients placed
             under legal guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sylvia Franc, MD</last_name>
    <email>sylvia.franc@free.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49933</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Séverine Dubois, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Allix, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Henri Duffaut</name>
      <address>
        <city>Avignon</city>
        <zip>84902</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Eric Benamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Françoise Plat, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Boulogne sur Mer</city>
        <zip>62321</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Véronique Kerlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Emmanuel Sonnet, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Alpes-Léman</name>
      <address>
        <city>Contamine sur Arve</city>
        <zip>74130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Sud-Francilien</name>
      <address>
        <city>Corbeil-Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sylvia Franc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alfred Penfornis, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guillaume Charpentier, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ahmed Daoudi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Louis Pasteur</name>
      <address>
        <city>Dole</city>
        <zip>39108</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Muriel Tschudnowski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Douai</city>
        <zip>59507</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Régis Bresson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Pierre Zobda-Quitman</name>
      <address>
        <city>Fort De France</city>
        <zip>97261</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Universitaire</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pierre-Yves Benhamou, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine Lablanche-Cornali, MD PHD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondation Hôtel Dieu du Creusot</name>
      <address>
        <city>Le Creusot</city>
        <zip>71200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sylvaine Clavel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anne Vambergue, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Baudoux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Lyon</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Charles Thivolet, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de la Conception</name>
      <address>
        <city>Marseille</city>
        <zip>13005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Pauline Schaepelynck, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Françoise Jannot-Lamotte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clémence Treglia, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Merignac</city>
        <zip>33700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Navaranne Roumec, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne Navaranne Roumec, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <address>
        <city>Noisy le Grand</city>
        <zip>93160</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Lariboisière</name>
      <address>
        <city>Paris</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Anne-Marie Leguerrier, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier</name>
      <address>
        <city>Saint Dié des Vosges</city>
        <zip>88187</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Pascal Mattei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Nathalie Jeandidier, MD PHD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dominique Paris, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>François Moreau, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Bernard</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Les Portes du Sud</name>
      <address>
        <city>Venissieux</city>
        <zip>69200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2015</study_first_submitted>
  <study_first_submitted_qc>August 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2015</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

